Devarashetty Sindhu, Chennapragada Suma Sri, Mansour Richard
Hematology and Oncology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, USA.
Internal Medicine, Louisiana State University Health Sciences Center-Shreveport, Shreveport, USA.
Cureus. 2022 May 18;14(5):e25098. doi: 10.7759/cureus.25098. eCollection 2022 May.
Cervical cancer is one of the leading causes of cancer mortality in women. However, there have been great advances in its prevention and treatment. Nevertheless, there are certain rare forms of this cancer that are under-recognized, underreported, and have a paucity of evidence in terms of treatment. Mesonephric adenocarcinoma (AC) is one such rare disease, with less than 50 cases reported in the literature so far. We report a case of mesonephric AC of the cervix in a 73-year-old female who presented with abnormal vaginal bleeding. Our case is unique in that the patient had recurrence with lung metastases as well as fibroblast growth factor receptor 2 (FGFR2) mutation on genetic sequencing. She responded well to platinum-based chemotherapy and is currently on maintenance therapy with lenvatinib and bevacizumab. We aim to bring this patient's disease course and treatment options chosen to the attention of the medical community as this is only the second reported case of mesonephric AC with FGFR2 mutation, and probably the first one to be treated with tyrosine kinase inhibitors and immunotherapy with a favorable response.
宫颈癌是女性癌症死亡的主要原因之一。然而,其预防和治疗已取得了巨大进展。尽管如此,这种癌症仍有某些罕见类型未得到充分认识、报告不足,且在治疗方面缺乏证据。中肾腺癌(AC)就是这样一种罕见疾病,迄今为止文献报道的病例不足50例。我们报告一例73岁女性宫颈中肾AC病例,该患者表现为异常阴道出血。我们的病例独特之处在于患者出现了肺转移复发,并且基因测序显示有成纤维细胞生长因子受体2(FGFR2)突变。她对铂类化疗反应良好,目前正在接受乐伐替尼和贝伐单抗维持治疗。我们旨在引起医学界对该患者病程及所选治疗方案的关注,因为这是第二例报告的伴有FGFR2突变的中肾AC病例,可能也是首例接受酪氨酸激酶抑制剂和免疫治疗且反应良好的病例。